TY - JOUR AU - Alifrangis, C. PY - 2019 DA - 2019// TI - Molecular and histopathology directed therapy for advanced bladder cancer JO - Nat Rev Urol. VL - 16 UR - https://doi.org/10.1038/s41585-019-0208-0 DO - 10.1038/s41585-019-0208-0 ID - Alifrangis2019 ER - TY - JOUR AU - Martinez Rodriguez, R. H. PY - 2017 DA - 2017// TI - Bladder cancer: present and future JO - Med Clin (Barc) VL - 149 UR - https://doi.org/10.1016/j.medcli.2017.06.009 DO - 10.1016/j.medcli.2017.06.009 ID - Martinez Rodriguez2017 ER - TY - JOUR AU - Antoni, S. PY - 2017 DA - 2017// TI - Bladder cancer incidence and mortality: a global overview and recent trends JO - Eur Urol VL - 71 UR - https://doi.org/10.1016/j.eururo.2016.06.010 DO - 10.1016/j.eururo.2016.06.010 ID - Antoni2017 ER - TY - JOUR AU - Pfannstiel, C. PY - 2019 DA - 2019// TI - The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes JO - Cancer Immunol Res VL - 7 UR - https://doi.org/10.1158/2326-6066.CIR-18-0758 DO - 10.1158/2326-6066.CIR-18-0758 ID - Pfannstiel2019 ER - TY - JOUR PY - 2014 DA - 2014// TI - Comprehensive molecular characterization of urothelial bladder carcinoma JO - Nature. VL - 507 UR - https://doi.org/10.1038/nature12965 DO - 10.1038/nature12965 ID - ref5 ER - TY - JOUR AU - Damrauer, J. S. PY - 2014 DA - 2014// TI - Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1318376111 DO - 10.1073/pnas.1318376111 ID - Damrauer2014 ER - TY - JOUR AU - Choi, W. PY - 2014 DA - 2014// TI - Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.01.009 DO - 10.1016/j.ccr.2014.01.009 ID - Choi2014 ER - TY - JOUR AU - Sjodahl, G. PY - 2012 DA - 2012// TI - A molecular taxonomy for urothelial carcinoma JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0077-T DO - 10.1158/1078-0432.CCR-12-0077-T ID - Sjodahl2012 ER - TY - JOUR AU - Yu, Z. PY - 2012 DA - 2012// TI - Cancer stem cells JO - Int J Biochem Cell Biol VL - 44 UR - https://doi.org/10.1016/j.biocel.2012.08.022 DO - 10.1016/j.biocel.2012.08.022 ID - Yu2012 ER - TY - JOUR AU - Cabrera, M. C. PY - 2015 DA - 2015// TI - Cancer stem cell plasticity and tumor hierarchy JO - World J Stem Cells VL - 7 UR - https://doi.org/10.4252/wjsc.v7.i1.27 DO - 10.4252/wjsc.v7.i1.27 ID - Cabrera2015 ER - TY - JOUR AU - Matsui, W. H. PY - 2016 DA - 2016// TI - Cancer stem cell signaling pathways JO - Medicine (Baltimore) VL - 95 UR - https://doi.org/10.1097/MD.0000000000004765 DO - 10.1097/MD.0000000000004765 ID - Matsui2016 ER - TY - JOUR AU - Plaks, V. PY - 2015 DA - 2015// TI - The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? JO - Cell Stem Cell VL - 16 UR - https://doi.org/10.1016/j.stem.2015.02.015 DO - 10.1016/j.stem.2015.02.015 ID - Plaks2015 ER - TY - JOUR AU - Shackleton, M. PY - 2009 DA - 2009// TI - Heterogeneity in cancer: cancer stem cells versus clonal evolution JO - Cell. VL - 138 UR - https://doi.org/10.1016/j.cell.2009.08.017 DO - 10.1016/j.cell.2009.08.017 ID - Shackleton2009 ER - TY - JOUR AU - Wei, J. PY - 2010 DA - 2010// TI - Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-0734 DO - 10.1158/1535-7163.MCT-09-0734 ID - Wei2010 ER - TY - JOUR AU - Santisteban, M. PY - 2009 DA - 2009// TI - Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-3343 DO - 10.1158/0008-5472.CAN-08-3343 ID - Santisteban2009 ER - TY - JOUR AU - Wu, C. T. PY - 2018 DA - 2018// TI - Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling JO - Ann Surg Oncol VL - 25 UR - https://doi.org/10.1245/s10434-018-6706-0 DO - 10.1245/s10434-018-6706-0 ID - Wu2018 ER - TY - JOUR AU - Li, Y. PY - 2017 DA - 2017// TI - Bladder cancer stem cells: clonal origin and therapeutic perspectives JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.19112 DO - 10.18632/oncotarget.19112 ID - Li2017 ER - TY - JOUR AU - Zhou, J. PY - 2007 DA - 2007// TI - Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0702596104 DO - 10.1073/pnas.0702596104 ID - Zhou2007 ER - TY - JOUR AU - Wang, Z. PY - 2008 DA - 2008// TI - Exploitation of the Notch signaling pathway as a novel target for cancer therapy JO - Anticancer Res VL - 28 ID - Wang2008 ER - TY - JOUR AU - Shachaf, C. M. PY - 2005 DA - 2005// TI - Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-1172 DO - 10.1158/0008-5472.CAN-05-1172 ID - Shachaf2005 ER - TY - JOUR AU - Yang, Z. PY - 2017 DA - 2017// TI - The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0882 DO - 10.1158/1078-0432.CCR-17-0882 ID - Yang2017 ER - TY - JOUR AU - Pinto, J. P. PY - 2015 DA - 2015// TI - StemChecker: a web-based tool to discover and explore stemness signatures in gene sets JO - Nucleic Acids Res VL - 43 UR - https://doi.org/10.1093/nar/gkv529 DO - 10.1093/nar/gkv529 ID - Pinto2015 ER - TY - JOUR AU - Jiang, P. PY - 2018 DA - 2018// TI - Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0136-1 DO - 10.1038/s41591-018-0136-1 ID - Jiang2018 ER - TY - JOUR AU - Hoshida, Y. PY - 2007 DA - 2007// TI - Subclass mapping: identifying common subtypes in independent disease data sets JO - PLoS One VL - 2 UR - https://doi.org/10.1371/journal.pone.0001195 DO - 10.1371/journal.pone.0001195 ID - Hoshida2007 ER - TY - JOUR AU - Yoshihara, K. PY - 2013 DA - 2013// TI - Inferring tumour purity and stromal and immune cell admixture from expression data JO - Nat Commun VL - 4 UR - https://doi.org/10.1038/ncomms3612 DO - 10.1038/ncomms3612 ID - Yoshihara2013 ER - TY - JOUR AU - Newman, A. M. PY - 2019 DA - 2019// TI - Determining cell type abundance and expression from bulk tissues with digital cytometry JO - Nat Biotechnol VL - 37 UR - https://doi.org/10.1038/s41587-019-0114-2 DO - 10.1038/s41587-019-0114-2 ID - Newman2019 ER - TY - JOUR AU - Langfelder, P. PY - 2008 DA - 2008// TI - WGCNA: an R package for weighted correlation network analysis JO - BMC Bioinformatics VL - 9 UR - https://doi.org/10.1186/1471-2105-9-559 DO - 10.1186/1471-2105-9-559 ID - Langfelder2008 ER - TY - JOUR AU - Tang, Z. PY - 2017 DA - 2017// TI - GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses JO - Nucleic Acids Res VL - 45 UR - https://doi.org/10.1093/nar/gkx247 DO - 10.1093/nar/gkx247 ID - Tang2017 ER - TY - JOUR AU - Inman, B. A. PY - 2017 DA - 2017// TI - Atezolizumab: a PD-L1-blocking antibody for bladder cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1417 DO - 10.1158/1078-0432.CCR-16-1417 ID - Inman2017 ER - TY - JOUR AU - Sidaway, P. PY - 2017 DA - 2017// TI - Bladder cancer: atezolizumab: an alternative to cisplatin? JO - Nat Rev Urol. VL - 14 ID - Sidaway2017 ER - TY - JOUR AU - Cattrini, C. PY - 2018 DA - 2018// TI - Atezolizumab and bladder cancer: facing a complex disease JO - Lancet. VL - 391 UR - https://doi.org/10.1016/S0140-6736(18)30095-3 DO - 10.1016/S0140-6736(18)30095-3 ID - Cattrini2018 ER - TY - JOUR AU - Gourd, E. PY - 2018 DA - 2018// TI - Neoadjuvant pembrolizumab in bladder cancer JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30814-3 DO - 10.1016/S1470-2045(18)30814-3 ID - Gourd2018 ER - TY - JOUR AU - Sarfaty, M. PY - 2018 DA - 2018// TI - Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer JO - Eur Urol VL - 74 UR - https://doi.org/10.1016/j.eururo.2018.03.006 DO - 10.1016/j.eururo.2018.03.006 ID - Sarfaty2018 ER - TY - JOUR AU - Sidaway, P. PY - 2017 DA - 2017// TI - Bladder cancer: pembrolizumab is superior to chemotherapy JO - Nat Rev Urol VL - 14 UR - https://doi.org/10.1038/nrurol.2017.38 DO - 10.1038/nrurol.2017.38 ID - Sidaway2017 ER - TY - STD TI - Roh W, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379):eaah3560. ID - ref35 ER - TY - JOUR AU - Nieto, M. A. PY - 2016 DA - 2016// TI - Emt: 2016 JO - Cell. VL - 166 UR - https://doi.org/10.1016/j.cell.2016.06.028 DO - 10.1016/j.cell.2016.06.028 ID - Nieto2016 ER - TY - JOUR AU - Ye, X. PY - 2015 DA - 2015// TI - Epithelial-mesenchymal plasticity: a central regulator of cancer progression JO - Trends Cell Biol VL - 25 UR - https://doi.org/10.1016/j.tcb.2015.07.012 DO - 10.1016/j.tcb.2015.07.012 ID - Ye2015 ER - TY - JOUR AU - Zhang, X. PY - 2015 DA - 2015// TI - Bladder cancer and genetic mutations JO - Cell Biochem Biophys VL - 73 UR - https://doi.org/10.1007/s12013-015-0574-z DO - 10.1007/s12013-015-0574-z ID - Zhang2015 ER - TY - JOUR AU - McConkey, D. J. PY - 2018 DA - 2018// TI - Molecular subtypes of bladder cancer JO - Curr Oncol Rep VL - 20 UR - https://doi.org/10.1007/s11912-018-0727-5 DO - 10.1007/s11912-018-0727-5 ID - McConkey2018 ER - TY - JOUR AU - Balbas-Martinez, C. PY - 2013 DA - 2013// TI - Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy JO - Nat Genet VL - 45 UR - https://doi.org/10.1038/ng.2799 DO - 10.1038/ng.2799 ID - Balbas-Martinez2013 ER - TY - JOUR AU - Ban, T. PY - 2018 DA - 2018// TI - Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus JO - Int Immunol VL - 30 ID - Ban2018 ER - TY - JOUR AU - Almuttaqi, H. PY - 2019 DA - 2019// TI - Advances and challenges in targeting IRF5, a key regulator of inflammation JO - FEBS J VL - 286 UR - https://doi.org/10.1111/febs.14654 DO - 10.1111/febs.14654 ID - Almuttaqi2019 ER - TY - JOUR AU - Krausgruber, T. PY - 2011 DA - 2011// TI - IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses JO - Nat Immunol VL - 12 UR - https://doi.org/10.1038/ni.1990 DO - 10.1038/ni.1990 ID - Krausgruber2011 ER - TY - JOUR AU - Li, Y. PY - 2014 DA - 2014// TI - GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens JO - Am J Cancer Res VL - 4 ID - Li2014 ER - TY - JOUR AU - Li, Y. PY - 2014 DA - 2014// TI - Loss of GATA3 in bladder cancer promotes cell migration and invasion JO - Cancer Biol Ther VL - 15 UR - https://doi.org/10.4161/cbt.27631 DO - 10.4161/cbt.27631 ID - Li2014 ER - TY - JOUR AU - Martinelli, P. PY - 2017 DA - 2017// TI - GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer JO - Gut. VL - 66 UR - https://doi.org/10.1136/gutjnl-2015-311256 DO - 10.1136/gutjnl-2015-311256 ID - Martinelli2017 ER - TY - JOUR AU - Peng, T. PY - 2019 DA - 2019// TI - The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma JO - Int J Oncol VL - 55 ID - Peng2019 ER - TY - JOUR AU - Kamijo, H. PY - 2018 DA - 2018// TI - Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-04-845834 DO - 10.1182/blood-2018-04-845834 ID - Kamijo2018 ER - TY - JOUR AU - Chia, N. Y. PY - 2015 DA - 2015// TI - Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development JO - Gut. VL - 64 UR - https://doi.org/10.1136/gutjnl-2013-306596 DO - 10.1136/gutjnl-2013-306596 ID - Chia2015 ER - TY - JOUR AU - Rosas, M. PY - 2014 DA - 2014// TI - The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal JO - Science. VL - 344 UR - https://doi.org/10.1126/science.1251414 DO - 10.1126/science.1251414 ID - Rosas2014 ER - TY - JOUR AU - Chen, A. F. PY - 2018 DA - 2018// TI - GRHL2-dependent enhancer switching maintains a pluripotent stem cell transcriptional subnetwork after exit from naive pluripotency JO - Cell Stem Cell VL - 23 UR - https://doi.org/10.1016/j.stem.2018.06.005 DO - 10.1016/j.stem.2018.06.005 ID - Chen2018 ER - TY - JOUR AU - Nishino, H. PY - 2017 DA - 2017// TI - Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression JO - Cancer Med VL - 6 UR - https://doi.org/10.1002/cam4.1212 DO - 10.1002/cam4.1212 ID - Nishino2017 ER - TY - JOUR AU - Goldhirsch, A. PY - 2013 DA - 2013// TI - Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt303 DO - 10.1093/annonc/mdt303 ID - Goldhirsch2013 ER - TY - JOUR AU - Coates, A. S. PY - 2015 DA - 2015// TI - Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv221 DO - 10.1093/annonc/mdv221 ID - Coates2015 ER - TY - JOUR AU - Curigliano, G. PY - 2017 DA - 2017// TI - De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx308 DO - 10.1093/annonc/mdx308 ID - Curigliano2017 ER - TY - JOUR AU - Burstein, H. J. PY - 2019 DA - 2019// TI - Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz235 DO - 10.1093/annonc/mdz235 ID - Burstein2019 ER - TY - JOUR AU - Liu, C. PY - 2019 DA - 2019// TI - Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+) T cell-derived interferon-gamma JO - Immunity. VL - 51 UR - https://doi.org/10.1016/j.immuni.2019.06.017 DO - 10.1016/j.immuni.2019.06.017 ID - Liu2019 ER - TY - JOUR AU - Tan, Y. PY - 2015 DA - 2015// TI - MFG-E8 is critical for embryonic stem cell-mediated T cell immunomodulation JO - Stem Cell Rep VL - 5 UR - https://doi.org/10.1016/j.stemcr.2015.09.005 DO - 10.1016/j.stemcr.2015.09.005 ID - Tan2015 ER - TY - JOUR AU - Jinushi, M. PY - 2011 DA - 2011// TI - Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1106645108 DO - 10.1073/pnas.1106645108 ID - Jinushi2011 ER - TY - JOUR AU - Cheetham, P. J. PY - 2016 DA - 2016// TI - New agents for the treatment of advanced bladder cancer JO - Oncology (Williston Park) VL - 30 ID - Cheetham2016 ER - TY - JOUR AU - Knowles, M. A. PY - 2015 DA - 2015// TI - Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc3817 DO - 10.1038/nrc3817 ID - Knowles2015 ER - TY - JOUR AU - Dongre, A. PY - 2019 DA - 2019// TI - New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer JO - Nat Rev Mol Cell Biol VL - 20 UR - https://doi.org/10.1038/s41580-018-0080-4 DO - 10.1038/s41580-018-0080-4 ID - Dongre2019 ER - TY - JOUR AU - Morel, A. P. PY - 2008 DA - 2008// TI - Generation of breast cancer stem cells through epithelial-mesenchymal transition JO - PLoS One VL - 3 UR - https://doi.org/10.1371/journal.pone.0002888 DO - 10.1371/journal.pone.0002888 ID - Morel2008 ER - TY - JOUR AU - Mani, S. A. PY - 2008 DA - 2008// TI - The epithelial-mesenchymal transition generates cells with properties of stem cells JO - Cell. VL - 133 UR - https://doi.org/10.1016/j.cell.2008.03.027 DO - 10.1016/j.cell.2008.03.027 ID - Mani2008 ER - TY - JOUR AU - Huang, Y. PY - 2018 DA - 2018// TI - Collagen type VI alpha 3 chain promotes epithelial-mesenchymal transition in bladder cancer cells via transforming growth factor β (TGF-β)/Smad pathway JO - Med Sci Monit VL - 24 UR - https://doi.org/10.12659/MSM.909811 DO - 10.12659/MSM.909811 ID - Huang2018 ER -